Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.20 USD
-0.07 (-5.51%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.21 +0.01 (0.83%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
NKTR 1.20 -0.07(-5.51%)
Will NKTR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NKTR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NKTR
Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
NKTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
Other News for NKTR
Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets
Nektar initiated with bullish view at Rodman & Renshaw
Oppenheimer Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
Nektar Therapeutics Likely To Drift And Wobble Ahead Of Key Phase II Data In 2025
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024